Epigenetic and genetic alterations-based molecular classification of head and neck cancer

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Hinerman RW, Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB. Postoperative irradiation for squamous cell carcinoma of the oral cavity: 35-year experience. Head Neck26(11), 984–994 (2004).
   PubMed Web of Science ®Google Scholar
• Stewart BW, Kleihues P. World Cancer Report: Head and Neck Cancer. IARC Press, Lyon, France, 232–236 (2003).
   Google Scholar
• Le QT, Giaccia AJ. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin. Cancer Res.9(12), 4287–4295 (2003).
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med.10(8), 789–799 (2004).
   PubMed Web of Science ®Google Scholar
• Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol.27(24), 4027–4034 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med.17(3), 330–339 (2011).
   PubMed Web of Science ®Google Scholar
• Esteller M, Fraga MF, Paz MF et al. Cancer epigenetics and methylation. Science297(5588), 1807–1808 (2002).
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature301(5895), 89–92 (1983).
   PubMed Web of Science ®Google Scholar
• Bird AP. DNA methylation – how important in gene control? Nature307(5951), 503–504 (1984).
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N. Engl. J. Med.358(11), 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Jones PA, Laird PW. Cancer epigenetics comes of age. Nat. Genet.21(2), 163–167 (1999).
   PubMed Web of Science ®Google Scholar
• Das PM, Singal R. DNA methylation and cancer. J. Clin. Oncol.22(22), 4632–4642 (2004).
   PubMed Web of Science ®Google Scholar
• Smith IM, Glazer CA, Mithani SK et al. Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One4(3), e4961 (2009).
   PubMedGoogle Scholar
• Doi A, Park IH, Wen B et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet.41(12), 1350–1353 (2009).
   PubMed Web of Science ®Google Scholar
• Meissner A, Mikkelsen TS, Gu H et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature454(7205), 766–770 (2008).
   PubMed Web of Science ®Google Scholar
• Lister R, Pelizzola M, Dowen RH et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature462(7271), 315–322 (2009).
   PubMed Web of Science ®Google Scholar
• Feinberg AP. Cancer epigenetics is no mickey mouse. Cancer Cell8(4), 267–268 (2005).
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Chromatin modifications and their function. Cell128(4), 693–705 (2007).
   PubMed Web of Science ®Google Scholar
• Allis CD, Berger SL, Cote J et al. New nomenclature for chromatin-modifying enzymes. Cell131(4), 633–636 (2007).
   PubMed Web of Science ®Google Scholar
• Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell128(4), 707–719 (2007).
   PubMed Web of Science ®Google Scholar
• Seligson DB, Horvath S, McBrian MA et al. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol.174(5), 1619–1628 (2009).
   PubMed Web of Science ®Google Scholar
• Manuyakorn A, Paulus R, Farrell J et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J. Clin. Oncol.28(8), 1358–1365 (2010).
   PubMed Web of Science ®Google Scholar
• Elsheikh SE, Green AR, Rakha EA et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res.69(9), 3802–3809 (2009).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase 3 randomized study. Cancer106(8), 1794–1803 (2006).
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol.20(10), 2429–2440 (2002).
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol.28(29), 4485–4491 (2010).
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM et al. Phase 2b multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol.25(21), 3109–3115 (2007).
   PubMed Web of Science ®Google Scholar
• Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res.21(3), 502–517 (2011).
   PubMed Web of Science ®Google Scholar
• Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA93(18), 9821–9826 (1996).
   PubMed Web of Science ®Google Scholar
• Frommer M, McDonald LE, Millar DS et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA89(5), 1827–1831 (1992).
   PubMed Web of Science ®Google Scholar
• Bibikova M, Lin Z, Zhou L et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res.16(3), 383–393 (2006).
   PubMed Web of Science ®Google Scholar
• Ai L, Vo QN, Zuo C et al. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol. Biomarkers Prev.13(1), 150–156 (2004).
   PubMed Web of Science ®Google Scholar
• El-Naggar AK, Lai S, Clayman G et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am. J. Pathol.151(6), 1767–1774 (1997).
   PubMed Web of Science ®Google Scholar
• Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol.7(1), 77–82 (2006).
   PubMed Web of Science ®Google Scholar
• Bennett KL, Romigh T, Arab K et al. Activator protein 2alpha (AP2alpha) suppresses 42 kDa C/CAAT enhancer binding protein a (p42(C/EBPalpha)) in head and neck squamous cell carcinoma. Int. J. Cancer124(6), 1285–1292 (2009).
   Google Scholar
• Kunimoto Y, Nakano S, Kataoka H, Shimada Y, Oshimura M, Kitano H. Deleted in esophageal cancer 1(DEC1) is down-regulated and contributes to migration in head and neck squamous cell carcinoma cell lines. ORL J. Otorhinolaryngol. Relat. Spec.73(1), 17–23 (2011).
   Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet.37(4), 391–400 (2005).
   PubMed Web of Science ®Google Scholar
• Rosas SL, Koch W, da Costa Carvalho MG et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res.61(3), 939–942 (2001).
   PubMed Web of Science ®Google Scholar
• Sanchez-Cespedes M, Esteller M, Wu L et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res.60(4), 892–895 (2000).
   PubMed Web of Science ®Google Scholar
• Chang HW, Chan A, Kwong DL, Wei WI, Sham JS, Yuen AP. Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. Int. J. Cancer105(6), 851–855 (2003).
   PubMed Web of Science ®Google Scholar
• Hamana K, Uzawa K, Ogawara K et al. Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Br. J. Cancer92(12), 2181–2184 (2005).
   PubMed Web of Science ®Google Scholar
• Ha PK, Chang SS, Glazer CA, Califano JA, Sidransky D. Molecular techniques and genetic alterations in head and neck cancer. Oral Oncol.45(4–5), 335–339 (2009).
   PubMed Web of Science ®Google Scholar
• Jin C, Jin Y, Wennerberg J, Annertz K, Enoksson J, Mertens F. Cytogenetic abnormalities in 106 oral squamous cell carcinomas. Cancer Genet. Cytogenet.164(1), 44–53 (2006).
   Google Scholar
• Patmore HS, Ashman JN, Stafford ND et al. Genetic analysis of head and neck squamous cell carcinoma using comparative genomic hybridisation identifies specific aberrations associated with laryngeal origin. Cancer Lett.258(1), 55–62 (2007).
   PubMed Web of Science ®Google Scholar
• Singh B, Gogineni S, Goberdhan A et al. Spectral karyotyping analysis of head and neck squamous cell carcinoma. Laryngoscope111(9), 1545–1550 (2001).
   Google Scholar
• An J, Liu Z, Hu Z et al. Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol. Biomarkers Prev.16(8), 1633–1638 (2007).
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Nakao H, Ikemura K, Katoh T. Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis. Oral Oncol.43(10), 1043–1048 (2007).
   Google Scholar
• De Schutter H, Spaepen M, McBride WH, Nuyts S. The clinical relevance of microsatellite alterations in head and neck squamous cell carcinoma: a critical review. Eur. J. Hum. Genet.15(7), 734–741 (2007).
   PubMed Web of Science ®Google Scholar
• Ogawara K, Miyakawa A, Shiba M et al. Allelic loss of chromosome 13q14.3 in human oral cancer: correlation with lymph node metastasis. Int. J. Cancer79(4), 312–317 (1998).
   Google Scholar
• Bockmuhl U, Schwendel A, Dietel M, Petersen I. Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinomas. Cancer Res.56(23), 5325–5329 (1996).
   Google Scholar
• Choi HR, Roberts DB, Johnigan RH et al. Molecular and clinicopathologic comparisons of head and neck squamous carcinoma variants: common and distinctive features of biological significance. Am. J. Surg. Pathol.28(10), 1299–1310 (2004).
   Google Scholar
• Coon SW, Savera AT, Zarbo RJ et al. Prognostic implications of loss of heterozygosity at 8p21 and 9p21 in head and neck squamous cell carcinoma. Int. J. Cancer111(2), 206–212 (2004).
   PubMed Web of Science ®Google Scholar
• Scholnick SB, Haughey BH, Sunwoo JB et al. Chromosome 8 allelic loss and the outcome of patients with squamous cell carcinoma of the supraglottic larynx. J. Natl Cancer Inst.88(22), 1676–1682 (1996).
   Google Scholar
• Guerin LA, Hoffman HT, Zimmerman MB, Robinson RA. Decreased fragile histidine triad gene protein expression is associated with worse prognosis in oral squamous carcinoma. Arch. Pathol. Lab. Med.130(2), 158–164 (2006).
   Google Scholar
• Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int. J. Exp. Pathol.86(6), 347–363 (2005).
   PubMed Web of Science ®Google Scholar
• Soni S, Kaur J, Kumar A et al. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology68(4–6), 314–325 (2005).
   PubMed Web of Science ®Google Scholar
• Blons H, Cabelguenne A, Carnot F et al. Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. Int. J. Cancer84(4), 410–415 (1999).
   PubMed Web of Science ®Google Scholar
• van ’t Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature452(7187), 564–570 (2008).
   Google Scholar
• Kuriakose MA, Chen WT, He ZM et al. Selection and validation of differentially expressed genes in head and neck cancer. Cell. Mol. Life Sci.61(11), 1372–1383 (2004).
   PubMed Web of Science ®Google Scholar
• Chung CH, Parker JS, Karaca G et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell5(5), 489–500 (2004).
   PubMed Web of Science ®Google Scholar
• Belbin TJ, Singh B, Barber I et al. Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res.62(4), 1184–1190 (2002).
   PubMed Web of Science ®Google Scholar
• Liu CJ, Liu TY, Kuo LT et al. Differential gene expression signature between primary and metastatic head and neck squamous cell carcinoma. J. Pathol.214, 489–497 (2008).
   Google Scholar
• Yan M, Xu Q, Zhang P, Zhou XJ, Zhang ZY, Chen WT. Correlation of NF-κB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma. BMC Cancer10, 437 (2010).
   PubMed Web of Science ®Google Scholar
• Roepman P, Wessels LF, Kettelarij N et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat. Genet.37(2), 182–186 (2005).
   PubMed Web of Science ®Google Scholar
• Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell10(6), 515–527 (2006).
   PubMed Web of Science ®Google Scholar
• Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J. Clin. Oncol.26(3), 354–360 (2008).
   PubMed Web of Science ®Google Scholar
• Liu W, Feng JQ, Shen XM, Wang HY, Liu Y, Zhou ZT. Two stem cell markers, ATP-binding cassette, G2 subfamily (ABCG2) and BMI-1, predict the transformation of oral leukoplakia to cancer: a long-term follow-up study. Cancer118(6), 1693–1700 (2011).
   Google Scholar
• Cao W, Younis RH, Li J et al. EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cancer Prev. Res. (Phila.)4(11), 1816–1824 (2011).
   Google Scholar
• Saintigny P, Zhang L, Fan YH et al. Gene expression profiling predicts the development of oral cancer. Cancer Prev. Res. (Phila.)4(2), 218–229 (2011).
   PubMed Web of Science ®Google Scholar
• Si P, Bakker E. Thin layer electrochemical extraction of non-redoxactive cations with an anion-exchanging conducting polymer overlaid with a selective membrane. Chem. Commun. (Camb.) (35), 5260–5262 (2009).
   Google Scholar
• D’Souza G, Kreimer AR, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med.356(19), 1944–1956 (2007).
   PubMed Web of Science ®Google Scholar
• Lopes V, Murray P, Williams H, Woodman C, Watkinson J, Robinson M. Squamous cell carcinoma of the oral cavity rarely harbours oncogenic human papillomavirus. Oral Oncol.47(8), 698–701 (2011).
   PubMed Web of Science ®Google Scholar
• Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer’s tonsillar ring. Cancer79(3), 595–604 (1997).
   PubMed Web of Science ®Google Scholar
• Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J. Clin. Oncol.24(17), 2606–2611 (2006).
   PubMed Web of Science ®Google Scholar
• Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer92(4), 805–813 (2001).
   PubMed Web of Science ®Google Scholar
• Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl Cancer Inst.100(4), 261–269 (2008).
   PubMed Web of Science ®Google Scholar
• Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science248(4951), 76–79 (1990).
   PubMed Web of Science ®Google Scholar
• Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell63(6), 1129–1136 (1990).
   PubMed Web of Science ®Google Scholar
• Hafkamp HC, Speel EJ, Haesevoets A et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in P53 exons 5–8. Int. J. Cancer107(3), 394–400 (2003).
   PubMed Web of Science ®Google Scholar
• Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin. Cancer Res.9(17), 6469–6475 (2003).
   PubMed Web of Science ®Google Scholar
• Wang Z, Sturgis EM, Zhang Y et al. Combined p53-related genetic variants together with HPV infection increase oral cancer risk. Int. J. Cancer doi:10.1002/ijc.27335 (2011) (Epub ahead of print).
   Google Scholar
• Gillison ML. Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. J. Clin. Oncol.24(36), 5623–5625 (2006).
   PubMed Web of Science ®Google Scholar
• Braakhuis BJ, Brakenhoff RH, Meijer CJ, Snijders PJ, Leemans CR. Human papilloma virus in head and neck cancer: the need for a standardised assay to assess the full clinical importance. Eur. J. Cancer45(17), 2935–2939 (2009).
   PubMed Web of Science ®Google Scholar
• Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol.24(17), 2666–2672 (2006).
   PubMed Web of Science ®Google Scholar
• Psyrri A, Yu Z, Weinberger PM et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin. Cancer Res.11(16), 5856–5862 (2005).
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res.62(24), 7350–7356 (2002).
   PubMed Web of Science ®Google Scholar
• Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu. Rev. Pathol.4, 49–70 (2009).
   PubMed Web of Science ®Google Scholar
• Sundvall M, Karrila A, Nordberg J, Grenman R, Elenius K. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. Expert Opin. Emerg. Drugs15(2), 185–201 (2010).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med.354(6), 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med.359(11), 1116–1127 (2008).
   PubMed Web of Science ®Google Scholar
• Petak I, Schwab R, Orfi L, Kopper L, Keri G. Integrating molecular diagnostics into anticancer drug discovery. Nat. Rev. Drug Discov.9(7), 523–535 (2010).
   PubMed Web of Science ®Google Scholar
• Callender T, El-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer74(1), 152–158 (1994).
   PubMed Web of Science ®Google Scholar
• Hunter T, Pines J. Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell79(4), 573–582 (1994).
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Almadori G, Cavallo S et al.Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin. Cancer Res.2(1), 175–180 (1996).
   PubMedGoogle Scholar
• Yu Z, Weinberger PM, Haffty BG et al. Cyclin D1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin. Cancer Res.11(3), 1160–1166 (2005).
   PubMedGoogle Scholar
• Wang CY, Guttridge DC, Mayo MW, Baldwin AS. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol.19(9), 5923–5929 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell3(2), 185–197 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhang Z, Zhou X, Qiu W, Chen F, Chen W. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer6, 224 (2006).
   PubMedGoogle Scholar
• Zhou X, Zhang Z, Yang X, Chen W, Zhang P. Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity. Int. J. Cancer124(2), 483–489 (2009).
   Google Scholar
• Feng Z, Guo W, Zhang C et al.CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS One6(10), e26399 (2011).
   Google Scholar
• Simon JA. Transcription. Sweet silencing. Science325(5936), 45–46 (2009).
   Google Scholar
• Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev.16(22), 2893–2905 (2002).
   PubMed Web of Science ®Google Scholar
• Cao R, Wang L, Wang H et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science298(5595), 1039–1043 (2002).
   PubMed Web of Science ®Google Scholar
• Kondo Y, Shen L, Cheng AS et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet.40(6), 741–750 (2008).
   PubMed Web of Science ®Google Scholar
• Vire E, Brenner C, Deplus R et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature439(7078), 871–874 (2006).
   PubMed Web of Science ®Google Scholar
• Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the Polycomb connection. Cell118(4), 409–418 (2004).
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M et al. The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature419(6907), 624–629 (2002).
   PubMed Web of Science ®Google Scholar
• Kikuchi J, Kinoshita I, Shimizu Y et al. Distinctive expression of the Polycomb group proteins Bmi1 Polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer116(12), 3015–3024 (2010).
   Google Scholar
• Gong Y, Huo L, Liu P et al. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer117(24), 5476–5484 (2011).
   Google Scholar
• He LR, Liu MZ, Li BK et al. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int. J. Cancer127(1), 138–147 (2010).
   PubMed Web of Science ®Google Scholar
• Kidani K, Osaki M, Tamura T et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol.45(1), 39–46 (2009).
   PubMedGoogle Scholar
• Cao W, Feng Z, Cui Z et al. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer doi:10.1002/cncr.26575 (2011) (Epub ahead of print).
   Google Scholar
• Hall GL, Kademani D, Risk JM, Shaw RJ. Tissue banking in head and neck cancer. Oral Oncol.44(2), 109–115 (2008).
   Google Scholar
• Spruessel A, Steimann G, Jung M et al. Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques36(6), 1030–1037 (2004).
   PubMed Web of Science ®Google Scholar
• Blackhall FH, Pintilie M, Wigle DA et al. Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. Neoplasia6(6), 761–767 (2004).
   Google Scholar
• Ghazani AA, Arneson NC, Warren K, Done SJ. Limited tissue fixation times and whole genomic amplification do not impact array CGH profiles. J. Clin. Pathol.59(3), 311–315 (2006).
   Google Scholar
• Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am. J. Pathol.158(2), 419–429 (2001).
   PubMed Web of Science ®Google Scholar
• Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med.2(9), 1035–1037 (1996).
   PubMed Web of Science ®Google Scholar
• Righini CA, de Fraipont F, Timsit JF et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin. Cancer Res.13(4), 1179–1185 (2007).
   PubMed Web of Science ®Google Scholar
• Ruesga MT, Acha-Sagredo A, Rodriguez MJ et al.p16(INK4a) promoter hypermethylation in oral scrapings of oral squamous cell carcinoma risk patients. Cancer Lett.250(1), 140–145 (2007).
   Google Scholar
• Bell WC, Sexton KC, Grizzle WE. Organizational issues in providing high-quality human tissues and clinical information for the support of biomedical research. Methods Mol. Biol.576, 1–30 (2010).
   Google Scholar
• Hunt JL, Finkelstein SD. Microdissection techniques for molecular testing in surgical pathology. Arch. Pathol. Lab. Med.128(12), 1372–1378 (2004).
   Google Scholar
• Holland NT, Smith MT, Eskenazi B, Bastaki M. Biological sample collection and processing for molecular epidemiological studies. Mutat. Res.543(3), 217–234 (2003).
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer6(11), 857–866 (2006).
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat. Rev. Cancer6(4), 259–269 (2006).
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA105(30), 10513–10518 (2008).
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang L, Wang A, Yu J, Shi F, Zhou X. MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett.286(2), 217–222 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang J, Sun Q, Zhang Z, Ge S, Han ZG, Chen WT. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene doi:10.1038/onc.2012.28 (2012) (Epub ahead of print).
   Google Scholar
• Stransky N, Egloff AM, Tward AD et al. The mutational landscape of head and neck squamous cell carcinoma. Science333(6046), 1157–1160 (2011).
   PubMed Web of Science ®Google Scholar
• Agrawal N, Frederick MJ, Pickering CR et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science333(6046), 1154–1157 (2011).
   PubMed Web of Science ®Google Scholar
• Mardis ER. A decade’s perspective on DNA sequencing technology. Nature470(7333), 198–203 (2011).
   PubMed Web of Science ®Google Scholar